Impact of hormonal status on ductal carcinoma in situ of the breast: Outcome and prognostic factors

Breast J. 2020 May;26(5):937-945. doi: 10.1111/tbj.13738. Epub 2019 Dec 26.

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease which is increasingly diagnosed through improved screening measures. Multiple prognostic scores have been devised to predict the risk of local recurrence (LR), and the optimal adjuvant management for DCIS is still debated. Hence, the aim of this analysis is to investigate the factors contributing to the prognosis of DCIS, in particular the role of its hormonal status. From 2005 to 2016, a total of 1221 female patients diagnosed with DCIS at the National Cancer Centre Singapore and Singapore General Hospital were studied. The mean age of diagnosis was 54 years of age (sd = 11.0), with estrogen receptor (ER)-positive DCIS tumors presenting earlier (mean age 54 vs 57 years of age; P < .001). DCIS with negative hormonal status (HS) correlates significantly with a larger size (mean 23.5mm vs 13.0 mm, P < .001) and higher grade of tumor (P < .001). Patients with positive HS were more likely to undergo breast conservation surgery over a mastectomy, in contrast to patients with negative HS (P < .001). Patients with negative HS had a poorer prognosis, with a shorter time of overall survival time (HR = 26.3, P = .020). In conclusion, our study shows that the hormonal status, age of diagnosis, and positive margins are important prognostic factors for DCIS, at least in our Asian population.

Keywords: Asia; breast cancer; ductal carcinoma in situ; hormone; oestrogen receptor.

MeSH terms

  • Breast Neoplasms* / therapy
  • Carcinoma, Ductal, Breast* / surgery
  • Carcinoma, Intraductal, Noninfiltrating* / surgery
  • Female
  • Humans
  • Mastectomy
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prognosis
  • Singapore